Anti-tumor drug supervision in China from2010 to 2024:the evolution and prospect of drug review standards  

作　　者：Ling Tang Yuanyuan Song Hong Zhang Ruimin Hao Xin Tong Xing Ai Jun Ma Zhimin Yang 

机构地区：[1]Office of Clinical Trial Management,Center for Drug Evaluation,National Medical Products Administration,Beijing,P.R.China [2]Office of Clinical Evaluation 1,Center for Drug Evaluation,National Medical Products Administration,Beijing,P.R.China [3]Harbin Institute of Hematology and Oncology,Harbin,Heilongjiang,P.R.China [4]Center for Drug Evaluation,National Medical Products Administration,Beijing,P.R.China

出　　处：《Cancer Communications》2025年第1期63-67,共5页癌症通讯(英文)

摘　　要：1 BACKGROUND Over the past decade,the research and development(R&D)of anti-tumor drugs in China has undergone a remarkable leap,maintaining a high level of motivation.

关 键 词：DRUGS EVOLUTION MOTIVATION 

分 类 号：F20[经济管理—国民经济]